Your Cart

Pro-Rata Renounceable Rights Issue

Pro-Rata Renounceable Rights Issue

Imagion Biosystems Limited has released “Pro-Rata Renounceable Rights Issue”. Highlight of this issue include:

  • Funds to complete the manufacture of nanoparticle material and initiate a first-in-human study (where sufficient capital is raised) and for general working capital
  • 2-for-5 pro-rata renounceable rights issue at an issue price of $0.01 per share to raise a up to approximately $2.04 million
  • Discount of 38% to the 30 day VWAP
  • With every New Share, shareholders will receive a free attaching New Option
  • New Options will have Exercise Price of 3.0 cents and a term of three years
  • Shortfall facility to enable applications for additional shares

Read the Pro-Rata Renounceable Rights Issue.

Related Articles

1H2023 Half-Year Results

1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.